Buy Alert for Acadia Pharmaceuticals (ACAD): Innovation Leader in Neurotherapy With Strong Growth Potential!
Reading Time: 2 minutes
Acadia Pharmaceuticals (ACAD) is particularly focused on the treatment of Parkinson's psychosis, Rett syndrome, and Alzheimer's psychosis. Parkinson's psychosis (PDP) affects about half of Parkinson's patients and manifests through hallucinations and delusions. Acadia has developed NUPLAZID (Pimavanserin), the first and only FDA-approved therapy for these symptoms. Rett syndrome is a rare neurodevelopmental disorder that primarily occurs in girls and affects approximately 1 in 10,000-15,000 female births worldwide. Acadia offers DAYBUE (Trofinetid),...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
